CJC-1295 no DAC

No published study in the cited literature has given CJC-1295 without DAC to a human being. People have taken CJC-1295, but the two human trials on record used the albumin-binding DAC version: one pair of randomized, placebo-controlled trials in healthy adults aged 21 to 61, and one overnight sampling study in healthy men aged 20 to 40. They measured hormone levels, not body composition, recovery, sleep or any health outcome.

So the human evidence attached to the name is real, and it belongs to a different molecule. The no-DAC peptide shares the modified GHRH(1-29) backbone but lacks the chemical group that latches onto albumin, and that group is what produced the week-long effects those trials reported.

It is not approved by the FDA, and WADA prohibits it in sport.

CJC-1295 no DAC, sold as modified GRF 1-29, is a short synthetic copy of the first 29 amino acids of growth hormone releasing hormone, the hypothalamic signal that tells the pituitary to release growth hormone. The original CJC-1295 was built by substituting four amino acids in that fragment and then adding a reactive maleimido group on a lysine at the end, designed to bond to circulating albumin. That added group is what the market calls the Drug Affinity Complex.

Remove the reactive group and what remains is the tetrasubstituted fragment on its own. Material filed in FDA's 2024 compounding docket is titled "CJC 1295 Modified GRF (1-29) (same as CJC 1295 w/out DAC)", which is where the two names meet. The names overlap; the pharmacology does not.

One Receptor, Two Very Different Clocks

Both forms are built to activate the GHRH receptor on pituitary somatotrophs, the cells that make growth hormone. Growth hormone in turn drives the liver to produce IGF-1. That chain is ordinary endocrine physiology and is not in dispute.

What differs is how long the signal lasts. In the 2005 rat work that introduced CJC-1295, albumin conjugates of the GRF(1-29) derivatives resisted breakdown by the enzyme dipeptidylpeptidase-IV in vitro, and the lead compound was still detectable in rat plasma beyond 72 hours, riding on albumin. That persistence came from the maleimido group, the part the no-DAC peptide does not have.

Why the DAC Results Do Not Carry Over

The striking human numbers for CJC-1295, a half-life measured in days and hormone levels raised for a week or more, are properties of albumin binding. A peptide that cannot bind albumin will clear on a different timescale, and none of the cited sources measured how fast the no-DAC form clears in people or what it does to GH and IGF-1 there. The receptor target is shared. The exposure, and therefore the effect, has not been studied for this form.

Borrowing the DAC trials is the central error. When a vendor or forum cites "clinical studies on CJC-1295", it is citing Teichman and Ionescu, both of which used the albumin-binding compound with a half-life near a week. Quoting a 2- to 10-fold GH rise next to a no-DAC product attaches a result to a molecule that never produced it.

The pulse argument is a hypothesis presented as a finding. The selling point for the no-DAC form is that a short-lived signal should mimic the body's own GHRH bursts better than a continuous one. That may be reasonable physiology, but no cited study tested it. The irony is that the only pulsatility data on record, from the DAC form, found pulse frequency and size were preserved even under continuous stimulation.

Raised GH is not a result in itself. Even for the DAC form, the measured endpoints were GH and IGF-1 concentrations. Muscle, fat, recovery, sleep and ageing were never endpoints. A hormone level going up is a marker moving, not a benefit delivered.

The label may not settle what is in the vial. CJC-1295, modified GRF 1-29, no DAC and with DAC are used loosely and sometimes interchangeably, and FDA's own compounding list carries a single undifferentiated CJC-1295 entry.

There is no human safety record for the no-DAC form in the cited literature. The safety information that exists concerns CJC-1295 generally or the DAC version specifically.

In the DAC trials in healthy adults, lasting up to 49 days, no serious adverse reactions were reported. FDA's compounding safety listing names "CJC-1295" without specifying a form, cites serious adverse events including increased heart rate and a systemic vasodilatory reaction, flags possible immunogenicity and peptide-related impurities in compounded product, and notes that available clinical data are limited. That entry sits among substances whose nominations were withdrawn by the nominators, with FDA's stated concerns still published.

Long-term effects of sustained GH-axis stimulation from either form were not studied in any cited source.

The fair summary is short. GHRH receptor biology is solid. The DAC form of CJC-1295 has a small body of human pharmacology showing it raises GH and IGF-1 for days in healthy volunteers. The no-DAC form has neither human pharmacokinetic data nor human outcome data in the cited record.

That makes the useful question, when someone recommends it, which study they mean. If the answer is one of the 2006 trials, the evidence is for a different molecule. If the answer is the pulse rationale, that is a reasonable idea nobody in the cited literature has tested in people.

Not the compound in the human trials. Teichman (2006) and Ionescu (2006) both studied the albumin-binding DAC version, whose activity lasted days because of that binding.

Not shown to change body composition, recovery or sleep. No cited study measured any of these, for either form.

Not FDA approved. FDA has not approved any CJC-1295 product, and its compounding listing does not say which form its single CJC-1295 entry covers.

Not permitted in tested sport. WADA names CJC-1295 under S2.2.4, and the GHRH-analogue class wording captures the no-DAC peptide regardless of how it is labelled.

I want to be straight about this one, because the name does a lot of quiet work. Search CJC-1295 and you find two real human trials with clean numbers. Look closer and both used the long-acting version. The no-DAC peptide people actually buy as modified GRF 1-29 has, in everything I could trace, no human data of its own.

That does not make it dangerous or useless. It makes it unknown in people, which is a different thing. The receptor biology is legitimate, and the pulse idea is not silly. But a sensible idea is where research starts, not where it ends.

What I will not do is let the DAC numbers stand in for the no-DAC product. If someone shows you a study, check which molecule it used. On this compound, that one question settles most of the argument.